North Carolina-based biotech Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding. Plenty of companies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results